Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma

Merck (MRK) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication.The CHMP has now recommended marketing approval of Keytruda in combination with chemotherapy (pemetrexed and platinum chemotherapy) for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma (MPM) ...